Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States.
Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) was positive. PTZ formulations commonly used in the United States today appear to be a rare cause for false-positive GM results.
Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Paschalis
P
Vergidis
Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Raymund R
RR
Razonable
MiraVista Diagnostics and Mirabella Technologies, Indianapolis, Indiana, USA.
L Joseph
LJ
Wheat
Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Lynn
L
Estes
Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Angela M
AM
Caliendo
Brigham and Women's Hospital, Boston, Massachusetts, USA.
Lindsey R
LR
Baden
University of Florida, College of Medicine, Gainesville, Florida, USA.
John R
JR
Wingard
University of Alabama, Birmingham, Alabama, USA.
John
J
Baddley
University of Kansas School of Medicine, Wichita, Kansas, USA.
Maha
M
Assi
Community Infectious Diseases, Indianapolis, Indiana, USA.
Steven
S
Norris
Wayne State University, Detroit, Michigan, USA.
Pranatharthi
P
Chandrasekar
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Ryan
R
Shields
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Hong
H
Nguyen
University of Nebraska Medical Center, Omaha, Nebraska, USA.
Alison
A
Freifeld
Indiana University, Infectious Diseases, Wishard Memorial Hospital, Indianapolis, Indiana, USA.
Richard
R
Kohler
Indiana University, Pediatric Infectious Diseases, Riley Memorial Hospital, Indianapolis, Indiana, USA.
Martin
M
Kleiman
Weill Cornell Medical Center, New York, New York, USA.
Thomas J
TJ
Walsh
Indiana University, Thoracic Transplantation Program, Indianapolis, Indiana, USA chage@iu.edu.
Chadi A
CA
Hage
D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis*; D001230:Aspergillus / Q000302:isolation & purification*; D003955:Diagnostic Tests, Routine / Q000379:methods*; D004340:Drug Contamination; D005189:False Positive Reactions; D005260:Female; D005690:Galactose / Q000031:analogs & derivatives; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods; D008351:Mannans / Q000097:blood*; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D010878:Piperacillin / Q000737:chemistry / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D044967:Serum / Q000737:chemistry*; D014481:United States
D000900:Anti-Bacterial Agents; D008351:Mannans; C012990:galactomannan; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin; D005690:Galactose